Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn's disease - Archive ouverte HAL Accéder directement au contenu
Communication Dans Un Congrès Année : 2019

Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn's disease

(1, 2) , (3) , (4) , (5) , (6) , (7) , (8) , (9) , (10) , (11, 12) , (13) , (14) , (2) , (3) , (4) , (5) , (7) , (15) , (6) , (13)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Dates et versions

hal-03552299 , version 1 (02-02-2022)

Identifiants

Citer

Mathurin Fumery, Laurent Peyrin-Biroulet, Stéphane Nancey, Romain Altwegg, Pauline Veyrard, et al.. Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn's disease. 14. Congress of ECCO, European Crohn’s and Colitis Organisation, Mar 2019, Copenhague, Denmark. ⟨10.1093/ecco-jcc/jjy222.023⟩. ⟨hal-03552299⟩
10 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More